论文部分内容阅读
目的 观察益生菌制剂培菲康对肝硬化大鼠的防治效果 ,探讨其治疗肝病的机理。方法 采用CCL4复合因素法制造肝硬化模型 ,进行肠道菌群培养及肝组织学检查。结果 (1)治疗组 G- 需氧杆菌数量明显低于模型组 (P<0 .0 5 ) ;(2 )治疗组肝细胞变性坏死程度明显轻于 C组 ;(3)电镜结果表明 T组肠粘膜绒毛高度及上皮连接均好于 C组 ,肝细胞器损伤轻于 C组。结论 培菲康可调整菌群失调 ,减少 G-需氧杆菌的定植 ,改善肝脏及肠粘膜的组织形态 ,提示口服益生菌制剂可作为肝病患者安全常规的用药。
Objective To observe the effect of probiotic Bacitracin on the prevention and treatment of liver cirrhosis in rats and to explore the mechanism of its treatment of liver disease. Methods CCL4 composite method was used to make the model of liver cirrhosis, and intestinal flora culture and liver histology examination were performed. Results (1) The number of G-aerobic bacterium in the treatment group was significantly lower than that in the model group (P <0.05); (2) The degree of hepatocyte degeneration and necrosis in the treatment group was significantly lower than that in the C group; (3) Intestinal mucosa villi height and epithelial connections are better than C group, liver cell damage less than C group. Conclusion Peficon can adjust the flora, reduce the colonization of G-aerobes and improve the morphology of the liver and intestinal mucosa, suggesting that oral probiotics can be used as a safe and routine drug for patients with liver disease.